Literature DB >> 33434959

Optimal Long-Acting Injectable Antipsychotic Management During COVID-19.

Sarah A MacLaurin1,2,3, Caitlin Mulligan2,3, Manjola Ujkaj Van Alphen2,3,4, Oliver Freudenreich2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33434959     DOI： 10.4088/JCP.20l13730

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  3 in total

1.  The impact of the Covid-19 pandemic on patients with schizophrenia.

Authors:  Antonio Vita; Stefano Barlati
Journal:  Eur Neuropsychopharmacol       Date:  2021-08-14       Impact factor: 4.600

2.  Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study.

Authors:  Kyle A McKee; Candice E Crocker; Philip G Tibbo
Journal:  BMC Psychiatry       Date:  2021-12-20       Impact factor: 3.630

3.  Long acting injectable antipsychotics: Uninterrupted use during the COVID-19 pandemic.

Authors:  Maria Nystazaki; Maria Karanikola
Journal:  J Psychiatr Ment Health Nurs       Date:  2021-03-10       Impact factor: 2.720
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.